@article{739eb6ce13af4be0adb8ebbf0e46182a,
title = "A multi-center study to improve understanding of pulmonary vascular disease through phenomics",
abstract = "The National Institutes of Health (NIH)/National Heart, Lung and Blood institute (NHLBI) launched an initiative, PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) that aims to augment the current pulmonary hypertension (PH) classification based on shared biological features. PVDOMICS will enroll 1500 participants with PH and disease and healthy comparators. Enrollees will undergo deep clinical phenotyping, and blood will be acquired for comprehensive omic analyses that will focus on discovery of molecular-based subtypes of pulmonary vascular disease (PVD) through application of high dimensional model-based clustering methods. In addition to an updated, molecular classification of PVD, the phenomic data generated will be a rich resource to the broad community of heart and lung disease investigators.",
keywords = "Blood Institute (U.S.), Diagnosis, Hypertension, Lung, National Heart, National Institutes of Health (U.S.), Pulmonary, Pulmonary artery",
author = "Hemnes, {Anna R.} and Beck, {Gerald J.} and Newman, {John H.} and Aiden Abidov and Aldred, {Micheala A.} and John Barnard and Rosenzweig, {Erika Berman} and Borlaug, {Barry A.} and Chung, {Wendy K.} and Comhair, {Suzy A.A.} and Erzurum, {Serpil C.} and Frantz, {Robert P.} and Gray, {Michael P.} and Gabriele Grunig and Hassoun, {Paul M.} and Hill, {Nicholas S.} and Horn, {Evelyn M.} and Bo Hu and Lempel, {Jason K.} and Maron, {Bradley A.} and Mathai, {Stephen C.} and Olman, {Mitchell A.} and Rischard, {Franz P.} and Systrom, {David M.} and Tang, {W. H.Wilson} and Waxman, {Aaron B.} and Lei Xiao and Yuan, {Jason X.J.} and Leopold, {Jane A.}",
note = "Funding Information: A.R. Hemnes has received grants from the National Institutes of Health. She has provided consultative services for Actelion, Bayer, GSK, and United Therapeutics. A. Abidov received research grant from Astellas Pharma. S.C. Erzurum chair the Pulmonary Disease American Board of Internal Medicine. R.P. Frantz is a Steering Committee member for Actelion, consultant for Bayer, consultant for DSMB, Adjudication Committee member for Lung LLC, consultant for St. Jude Medical, Steering Committee member for United Therapeutics and DSMB. N.S. Hill received research grants to institution Actelion, Bayer, Gilead, United Therapeutics, Scientific Advisory Boards, Actelion, Bayer, and Gilead. S.C. Mathai is a consultant for Actelion, Bayer, United Therapeutics Scientific Leadership Council, and Pulmonary Hypertension Association. F.P. Rischard received research funding, consulting, and advisory compensation from Bayer, Actelion, United Therapeutics, and Gilead. J.X.-J. Yuan is a member of the Steering Committee of the ENTELLIGENCE Young Investigator Program of Actelion. The other authors report no conflicts. Publisher Copyright: {\textcopyright} 2017 American Heart Association, Inc.",
year = "2017",
doi = "10.1161/CIRCRESAHA.117.311737",
language = "English (US)",
volume = "121",
pages = "1136--1139",
journal = "Circulation research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "10",
}